IB-Stim (neurostimulator)

History

2024: Product Announcement

In early November 2024, NeurAxis introduced the new IB-Stim non-implantable neurostimulator, which is mounted on the auricle. By triggering pulses of a certain frequency, IB-Stim is able to reduce the severity of functional abdominal pain in irritable bowel syndrome (IBS).

The NeurAxis system uses proprietary percutaneous electrical nerve field stimulation (PENFS) technology, thanks to which it delivers soft electrical impulses through the beams of craniocerebral nerves passing near the auricle. The device is intended to treat only functional pains, i.e. pains unrelated to organic causes, which often require emergency surgical treatment.

𝓲

IB-Stim

The device is designed to treat children and adolescents aged 8 to 21 years, and, according to the company, this is the only approved treatment for children with functional gastrointestinal disorders, which are based on a violation of the interaction of the intestine and brain.

NeurAxis President and CEO Brian Carrico noted that the company not only received regulatory approval, but also the possibility of reimbursement for the purchase of the device under insurance, starting in January 2026. Carrico expects an increase in revenue after the entry into force of this agreement.

"The regulatory approval obtained will allow us to significantly expand the distribution market of the IB-Stim neurostimulator to 75%," says Carrico. - In addition, the number of devices allocated per patient is expected to increase to four. These advances were made possible by a powerful body of published research that confirmed the effectiveness of our PENFS technology in clinical practice^[1]

Notes